Articles

BHS guidelines on supportive care in lymphoma: Part 2

BJH - volume 13, issue 4, june 2022

M. Janssens MD, K. Saevels MD, V. Vergote MD, J. Lemmens MD, S. Bailly MD, A. Janssens MD, PhD, S. Snauwaert MD, PhD, M. André MD, PhD

SUMMARY

Besides disease-directed therapy, patients with lymphoma are in need of a wide range of supportive measures. In the second part of this guideline, the prevention and treatment of tumour lysis syndrome, cardiac support and physiotherapy are discussed.

(BELG J HEMATOL 2022;13(4):149–55)

Read more

BHS guidelines on supportive care in lymphoma: Part 1

BJH - volume 13, issue 3, may 2022

M. Janssens MD, K. Saevels MD, V. Vergote MD, J. Lemmens MD, S. Bailly MD, A. Janssens MD, PhD, S. Snauwaert MD, PhD, M. André MD, PhD

SUMMARY

Besides disease-directed therapy, patients with lymphoma are in need of a wide range of supportive measures. In the first part of this guideline the use of anti-emetic therapy, the use of granulocyte colony stimulating factor (G-CSF) and antibiotic prophylaxis for pneumocystis jirovecii are discussed. In part 2 of this guideline we will discuss cardiac support, prevention and treatment of tumour lysis syndrome and the role of physiotherapy.

(BELG J HEMATOL 2022;13(3):116–23)

Read more

Highlights in aggressive lymphoma

BJH - volume 12, issue 1, february 2021

V. Vergote MD

SUMMARY

Hundreds of interesting oral abstracts and poster presentations were presented at this year’s – first ever- virtual 62nd Annual Meeting of ASH. In this article, I will highlight the most promising data regarding diffuse large B-cell lymphoma (DLBCL), Mantle Cell Lymphoma (MCL) and T-cell non-Hodgkin’s lymphoma (T-NHL).

(BELG J HEMATOL 2021;12(1):17-21)

Read more

BHS guidelines for the treatment of newly diagnosed diffuse large B-cell lymphoma (DLBCL) anno 2020

BJH - volume 11, issue 2, march 2020

G. Swennen MD, A. Janssens MD, PhD, V. Vergote MD, S. Bailly MD, C. Bonnet MD, PhD, E. Van den Neste MD, PhD, M. Maerevoet MD, S. Snauwaert MD, PhD, K. Saevels MD, C. Jacquy MD

SUMMARY

Diffuse large B-cell lymphoma is the most common subtype of non-Hodgkin lymphoma. Prognosis of diffuse large B-cell lymphoma has improved dramatically since the introduction of rituximab and about two thirds of patients can be cured with immunochemotherapy. In the last twenty years, it became clear that diffuse large B-cell lymphoma is a very heterogeneous disease and based on the genetic mutation landscapes numerous efforts have been made to develop novel treatment strategies to improve the prognosis of diffuse large B-cell lymphoma further. This article provides an update of diagnosis, current treatment guidelines and novel treatment strategies for newly diagnosed patients with diffuse large B-cell lymphoma in Belgium. It will also focus on treatment of elderly patients and high-grade B-cell lymphoma.

(BELG J HEMATOL 2020;11(2):56–66)

Read more

Updated BHS guidelines for the treatment of chronic lymphocytic leukaemia, mantle cell lymphoma and Waldenström macroglobulinemia anno 2018

BJH - volume 9, issue 3, june 2018

A. Janssens MD, PhD, V. Vergote MD, V. Van Hende MD, D. Bron MD, PhD, A. Van Hoof MD, PhD

SUMMARY

The Belgian Haematological Society Lymphoproliferative Working Party updated the existing recommendations on best strategies for frontline and subsequent line treatment of small lymphocytic leukaemia/chronic lymphocytic leukaemia, mantle cell lymphoma and Waldenström Macroglobulinemia according to new reimbursements and robust clinical data.

(BELG J HEMATOL 2018;9(3):101–12)

Read more

P37 Comparison of Multigam® IV (5% vs. 10%) in hematological patients with secondary immunodeficiencies to evaluate infusion time, tolerability and satisfaction. A monocentric observational Belgian study

BJH - 2018, issue Abstract Book BHS, february 2018

Ir J. Van Ham , M. Delforge MD, PhD, A. Janssens MD, PhD, J. Raddoux , M. Beckers MD, PhD, T. Devos MD, PhD, D. Dierickx MD, PhD, V. Vergote MD, J. Maertens MD, PhD, H. Schoemans MD, PhD, P. Vandenberghe MD, PhD

Read more

CNS prophylaxis in aggressive non-Hodgkin’s lymphoma

BJH - volume 8, issue 6, october 2017

C. Meert MD, D. Dierickx MD, PhD, V. Vergote MD, G. Verhoef MD, PhD, A. Janssens MD, PhD

SUMMARY

Although it doesn’t occur frequently, central nervous system relapse in aggressive non-Hodgkin lymphoma carries a very dismal prognosis. Indications for the use of prophylactic strategies are clear-cut in Burkitt and lymphoblastic lymphoma. However, this remains subject to much debate in other types of aggressive non-Hodgkin lymphoma, like diffuse large B-cell lymphoma. Available strategies consist of intrathecal administration of chemotherapy, the systemic use of high-dose central nervous system-penetrating cytotoxic agents or a combination of both. Nevertheless, all known methods entail a certain risk for toxicity in patients. Hence, great effort has been put in the search for risk factors and scores to identify high-risk patients who have benefit from central nervous system-prophylaxis and to exclude those who do not. This article aims to provide an overview of existing strategies, pharmacological properties and side effects of available cytotoxic agents, as well as an update on the current guidelines for the implementation of central nervous system prophylaxis in different types of non-Hodgkin lymphoma. However, due to lack of qualitative prospective data, a golden standard in this field is still lacking.

(BELG J HEMATOL 2017;8(6):232–8)

Read more
X